QCG
GTHX

Quadrant Capital Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Quadrant Capital Group’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-130
Closed -$706 – 2806
2022
Q4 		$706 Buy
+130
New +$1.09K ﹤0.01% 2588

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quadrant Capital Group's GTHX Position: Q1 2023 in Review

Quadrant Capital Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 130 shares — an estimated $706 sold.

Quadrant Capital Group first reported a position in GTHX in Q4 2022 and held it in 1 quarter. The position peaked at $706 in Q4 2022. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

  • Quadrant Capital Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 130 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $706.
  • Quadrant Capital Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Quadrant Capital Group's G1 Therapeutics, Inc. Common Stock position peaked at $706 in Q4 2022.
  • 96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Quadrant Capital Group's 13F filing for Q1 2023, filed 11 May 2023.